Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | QDPR | P09417 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24434719 | 1.00 | PIK3CD (0.39) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL24434580 | 0.79 | EPHX2 (0.42) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL14317303 | 0.79 | EPHX2 (0.42) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL2666145 | 0.77 | EPHX2 (0.53) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL15523084 | 0.76 | EPHX2 (0.40) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL13735645 | 0.76 | EPHX2 (0.40) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL24434765 | 0.74 | ACHE (0.33) | — | |
| SCHEMBL57712 | 0.74 | CYP1A2 (0.44) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL2998445 | 0.74 | CYP1A2 (0.44) | PIK3CDEPHX2EPHX1CYP1A2TDP1 | |
| SCHEMBL21846307 | 0.72 | EPHX2 (0.43) | PIK3CDEPHX2EPHX1CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | PIK3CD 1573/4885EPHX2 3730/4885EPHX1 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.